Successful Regulatory Exchange on 3D Mucosal Models for Vaccine Development at RIVM
The third Inno4Vac Subtopic 3 (MERMAID) Regulatory stakeholder meeting- “A regulatory exchange on characterization and qualification of...
top of page
Newsroom
Check on Inno4Vac latest news
- Jun 4
Inno4Vac interim review: advancing scientific and technological progress
On May 21-22 the Inno4Vac interim technical review successfully virtually took place.
73
- Jun 3
Face to face VAXPRED meeting 31st May 2024
Representatives from all partner institutions met to discuss the progress of VAXPRED, the Subtopic 1 of Inno4Vac project
82
- Feb 22
Four Key Reports highlighting regulatory and ethical aspects of the Controlled Human Infection Models
The Inno4Vac project aims to develop advanced and safe Controlled Human Infection Models (CHIMs) that can improve and accelerate vaccine...
159
- Jan 31
New findings on vaccine efficacy prediction: comprehensive antibody repertoire profiling
January 2024 -Inno4Vac Subtopic 1 (VAXPRED), which is dedicated to building an open access and cloud-based platform to predict vaccine...
133
- Jan 16
Regulatory engagement – continuing dialogue between ST4 model developers and EMA QIG
January 2024 Inno4Vac sub-topic 4 (VaXinS) aims to develop a hybrid model (a combination of a Compartmental Model [CM] and Kinetic...
118
- Oct 18, 2023
Annual Meeting 2023 Inno4Vac: innovations to accelerate vaccine development and manufacture
October 2023 To advance the ambitious programme of Inno4Vac – which aims to harness the latest advances in immunology, disease modelling,...
178
- Oct 16, 2023
Online platform on bio-manufacturing: workshop on integrating in silico models of unit operations
October 2023 Subtopic 4 ‘VAXinS’ of Inno4Vac is developing a modular one-stop computational platform for in silico modelling of vaccine...
253
- Oct 4, 2023
Towards controlled human Clostridioides difficile colonization and infection
04 October 2023 The recent 13th International Conference on the Molecular Biology and Pathogenesis of Clostridia (CLOSTPATH), in Banff,...
140
- Sep 11, 2023
1st Inno4Vac newsletter is out!
We are pleased to share the 1st Inno4Vac newsletter where you will find a summary of the communication efforts by EVI over the last few...
47
- Aug 10, 2023
The Inno4Vac Scientific and Ethics Advisory Committee has been appointed
August 2023 Inno4Vac announces the nomination of the independent Scientific and Ethics Advisory Committee (SEAC) of the Inno4Vac project....
68
- Jun 28, 2023
A regulatory exchange on diversity and standardisation of 3D mucosal models for vaccine development
The 2nd Inno4Vac ST3 (MERMAID) Regulatory stakeholder meeting was held June 27-28 and hosted by the Paul-Ehrlich-Institut in Langen, GE.
422
- May 17, 2023
Subtopic 1 VAXPRED meeting on 8-9 May 2023
16 May 2023 The subtopic1, VAXPRED, dedicated to build an open access and cloud-based platform to predict vaccine efficacy using...
149
- Nov 16, 2022
Annual Meeting 2022 Inno4Vac: innovations to accelerate vaccine development and manufacture
16 November 2022 To advance the ambitious programme of Inno4Vac, which aims to harness the latest advances in immunology and disease...
532
- Dec 14, 2021
First CHIMICHURRI workshop: developing a strategy for new challenge flu and RSV strain selection
14 December 2021 The subtopic 2, CHIMICHURRI, dedicated to the development of new and improved Control Human Infection Models (CHIM) for...
322
- Sep 29, 2021
Inno4Vac kick-off meeting brings together over 150 partners
29 September 2021 The kick-off meeting of Inno4Vac, a project that targets faster vaccine development and manufacture, by harnessing the...
120
- Jul 29, 2021
EVI to lead Inno4Vac, a new European public-private partnership to innovate vaccine development
The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking mobilised more than € 38.5 million to support Inno4Vac, an innovative...
124
bottom of page